VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report issued on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Up 3.9 %

NASDAQ:VBIV opened at $0.60 on Monday. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $10.47. The stock has a market cap of $14.28 million, a P/E ratio of -0.05 and a beta of 1.92. The firm’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.63.

Institutional Trading of VBI Vaccines

A number of hedge funds have recently modified their holdings of VBIV. State Street Corp increased its position in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company’s stock valued at $26,920,000 after purchasing an additional 3,844,698 shares during the last quarter. Millennium Management LLC increased its position in shares of VBI Vaccines by 211.7% during the 2nd quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company’s stock valued at $1,440,000 after purchasing an additional 1,209,393 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of VBI Vaccines by 358.7% during the 2nd quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 617,400 shares during the last quarter. Captrust Financial Advisors increased its position in shares of VBI Vaccines by 2,006,000.0% during the 3rd quarter. Captrust Financial Advisors now owns 601,830 shares of the biopharmaceutical company’s stock valued at $425,000 after purchasing an additional 601,800 shares during the last quarter. Finally, Frontier Wealth Management LLC grew its stake in shares of VBI Vaccines by 1,571.7% during the 1st quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company’s stock valued at $951,000 after acquiring an additional 565,800 shares during the period. Institutional investors own 12.26% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.